NCT06369155View on ClinicalTrials.gov

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 5, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Uterine Serous CarcinomaUterine CarcinomaUterine Cancer
Interventions
DRUG

Azenosertib

Wee1 inhibitor, 25mg and 100mg tablets, taken orally per protocol.

Trial Locations (2)

02215

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Zentalis

UNKNOWN

lead

Joyce Liu, MD

OTHER